



Italian Journal of Medicine

<https://www.italjmed.org/ijm>

eISSN 1877-9352

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Early Access service lets users access peer-reviewed articles well before print/regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Italian Journal of Medicine** is, therefore, E-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination, and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

The E-publishing of this PDF file has been approved by the authors.

Ital J Med 2026 [Online ahead of print]

Please cite this article as:

Di Bartolomeo S, Carubbi F, Liberatore E, et al. **Neurolisteriosis with a stroke-like presentation in a male adult with polymyalgia rheumatica: a case report and literature review.** *Ital J Med* doi: 10.4081/itjm.2026.2619

Submitted: 31-05-2026

Accepted: 09-09-2026

© the Author(s), 2026
Licensee PAGEPress, Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Neurolisteriosis with a stroke-like presentation in a male adult with polymyalgia rheumatica: a case report and literature review

Salvatore Di Bartolomeo,¹ Francesco Carubbi,² Ester Liberatore,¹ Serena Pasquarelli,¹
Piero Francesco Agrippino,¹ Luigi Evandro Aloisantonio,¹ Flavio Romolo Rispoli¹

¹Internal Medicine Division, ASL1 Avezzano-Sulmona-L'Aquila, SS. Annunziata Hospital, Sulmona; ²Internal Medicine and Nephrology Division, Department of Clinical Medicine, Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Italy

Correspondence: Serena Pasquarelli, Internal Medicine Division, ASL1 Avezzano-Sulmona-L'Aquila, SS. Annunziata Hospital, Sulmona, Italy. E-mail: serena.pasquarelli@alice.it

Key words: *Listeria monocytogenes*, neurolisteriosis, methotrexate, glucocorticoids, polymyalgia reumatica, case report.

Contributions: Salvatore Di Bartolomeo and Francesco Carubbi: study concept, draft of the manuscript. Ester Liberatore, Serena Pasquarelli, Piero Francesco Agrippino, Luigi Evandro Aloisantonio and Flavio Romolo Rispoli: clinical data collection and interpretation. All authors approved the final version.

Conflict of interest: the authors declare no conflicts of interests.

Ethics approval and consent to participate: the study followed the principles of the Declaration of Helsinki as revised in 2013. According to the guidelines of the Ethics Committee of ASL1 Avezzano-Sulmona-L'Aquila, publication of single case reports is exempt from formal ethics approval.

Patient consent for publication: written informed consent was obtained from the patient for publication of this case report.

Availability of data and materials: all data underlying the findings are fully available.

Declaration of generative artificial intelligence and artificial intelligence-assisted technologies in the writing process: authors did not use artificial intelligence and artificial intelligence-assisted technologies in the writing process.

Abstract

Listeria monocytogenes is a gram-positive bacillus that can cause a wide spectrum of clinical manifestations, ranging from paucisymptomatic to life-threatening disease. Central nervous system involvement is called neurolisteriosis and is a rare and severe entity that includes meningitis, meningoencephalitis, rhombencephalitis, and brain abscess, and it may start with a stroke-like presentation. People with rheumatic diseases taking immunosuppressive medications are at increased risk, and they also can have atypical presentations, misleading the diagnosis of infection. Magnetic resonance imaging can guide the diagnosis; however, a high clinical suspicion and a microbiological confirmation are needed. Here we present a case of *Listeria monocytogenes* brain abscess mimicking an ischemic stroke that occurred in a male patient with a previous diagnosis of polymyalgia rheumatica under immunosuppressive treatment. A literature revision was also performed.

Introduction

Listeria monocytogenes is a short gram positive, facultative anaerobic, non-spore forming, facultative intracellular bacillus belonging to the phylum Firmicutes, class Bacilli, order Bacillales, recognized as a human foodborne pathogen in the 1980s.¹⁻⁵ *L. monocytogenes* infection, called listeriosis, is mainly a food-borne disease contracted through the ingestion of contaminated products such as processed meat, dairy products, pre-packed sandwiches, cold-smoked fish, prepared vegetables, salads, fruits and frozen foods like ice-cream among others. Transmission follows the fecal-oral route; many cases are sporadic, but food-borne outbreaks are observed.³ *L. monocytogenes* remains one of the mains of food-borne diseases with the highest mortality rate,^{3,6,7} with an estimated incidence ranging from 0.1 to 11.3 cases per million population per year, depending on the geographic region.³ *L. monocytogenes* has many virulence factors: it can bind primary to gastrointestinal epithelial cells via cadherins entry, spreading through the cytosol and cell-to cell (thus escaping host antibody response), producing biofilms and disseminate hematogenously.^{3,7} Moreover, it can be spread by the macrophages throughout the reticulo-endothelial system and it can penetrate the blood-brain barrier as well as the placenta-fetus barrier.^{3,7-12}

Listeriosis spectrum ranges from subclinical, or mild self-limiting, febrile gastro-enteritis (in particular in immunocompetent hosts) to invasive, potentially deadly, disease.^{3,7,13} Risk factors for invasive disease are: pregnancy, extreme ages (e.g. neonates and elderly), cancer or other causes of immunosuppression. Invasive dis; ii) septicemic listeriosis; iii) central nervous system (CNS) infection called neurolisteriosis (NL). Less common infection sites include: peritoneal cavity, musculoskeletal system, eyes, cardiovascular system, urinary and biliary tract, skin among others.³ Polymyalgia reumatica (PMR) is a systemic, inflammatory, multifactorial, rheumatic disorder that affects people older than 50 with a female:male ratio of 2-3:1 and is more frequent in people of northern descend.¹⁴ It is characterized by musculoskeletal inflammatory pain in the pelvic and scapular girdle and neck variably associated with fatigue, arthralgia, lack of appetite, weight loss, non-erosive synovitis and fever. In up to 30% of cases it can be associated with giant cell arteritis (GCA), and PMR occurring in up to 50% of patients with GCA.^{14,15} According to the American College of Rheumatology/European League Against Rheumatism recommendations, treatment of PMR is primarily based on glucocorticoids (GCs) with a gradual tapering according to clinical response and, in patients with relapsing/refractory PMR or with intolerance to GCs due to comorbidities or with poor prognostic factors, conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) such methotrexate (MTX) or biologic (b) DMARDs, such as anti-IL-6 compounds, with the aim of steroid sparing effect.¹⁶⁻¹⁸

PMR treatments are associated with increased infection risk, and also GCs usage is associated with a relative and absolute increased risk of all cause bacterial, viral, fungal and parasitic infections in a dose and time dependent manner with elderly patients at increased mortality risk.¹⁹⁻²¹ MTX usage is also associated with an increased risk of non-serious infections, included febrile neutropenia, however by reducing the cumulative dose of GCs it could paradoxically reduce this risk.^{21,22} Similar considerations can be extended to the usage of Anti-IL 6 drugs with observational studies observed an increased risk of lung infections.¹⁶⁻²²

Here we present a case of *L. monocytogenes* brain abscess mimicking an ischemic stroke occurred in a male patient with a previous diagnosis of PMR under immunosuppressive treatment. A literature revision was also performed. Written informed consent was obtained from the patient for publication of this case report.

Case Report

In March 2025, a 73 year old Caucasian male was admitted to our Internal Medicine Unit on march 2025 due to the acute onset of left upper limb weakness, dysarthria, and mental confusion on the day before the admission. His medical history included: parkinsonism, hypertensive heart disease with paroxysmal atrial fibrillation on direct anticoagulant drug (DOAC), and benign prostatic hyperplasia. Eight months before the presentation, he received a diagnosis of PMR without GCA, due to the

presence of inflammatory pain to scapular and pelvic girdle with wrists arthritis increased inflammatory markers and negative autoantibodies (e.g., rheumatoid factor, anti-cyclic citrullinated peptides and antinuclear antibodies).

A treatment with prednisone (PDN) and MTX was started in another rheumatological center. We do not know why it started MTX as first line treatment because the patient was evaluated in another center, but we can speculate it was started due to the articular involvement as a steroid sparing agent. He has a good response on articular manifestations and inflammatory markers.

On current hospital admission he was regularly taking PDN 10 mg per day and MTX 15 mg subcutaneously every week with folic acid supplementation 24 hours after MTX dose. Other chronic medications were: Rivaroxaban 20 mg/d, Ramipril 5 mg/d and Carvedilol 2.5 mg/d.

In the context of pre-existing parkinsonism and chronic vascular burden, its Charlson Comorbidity Index was 6 and Clinical Frailty Scale score was of 6, indicating moderately frail.²³⁻²⁵

Physical examination revealed right upper limb hypertonia (spasticity) and left-sided hemi-inattention. Initial brain computed tomography (CT) suggested a left parietal ischemic lesion. Laboratory findings showed C-reactive protein 98 mg/L (normal value, n.v. 0-5), erythrocyte sedimentation rate 55 mm/h (n.v. 1-20), serum ferritin level 686 ng/mL (n.v. 21.8-274.6), serum iron 30µg/dL (n.v.65-175), slight hypogammaglobulinemia 0.69 gr/dL (n.v. 0.80-1.35). Other laboratory tests were normal, including procalcitonin, leukocyte count with conserved differential, electrolytes, coagulation panel and hepato-renal function, metabolic profile, thyroid function tests, folic acid, cobalamin, homocysteine, Widal-Wright reaction, anti-HIV 1/2 antibodies.

After the neurologist consultation, a diagnosis of ischemic stroke was made without indication for reperfusion due the time lapse and the CT results. DOAC was temporary stopped due to the risk of bleeding and acetylsalicylic acid was started.

Despite initial management, after 2 days, the patient developed remittent fever, worsening of left sided weakness evolving in a left sided hemiplegia and a decline in consciousness becoming drowsy. A contrast enhanced magnetic resonance imaging (MRI) of the brain showed a large abscess in the right parietal lobe with deep extension in the capsulo-thalamic region, compression of lateral ventricle and involvement of the corresponding leptomeningeal space.

Cerebrospinal fluid (CSF) analysis was clear with no leukocytes and erythrocyte, normal glucose but hyperproteinorrachia 154,30 mg/dL (n.v. 15-45). An empirical antibiotic therapy with ceftriaxone 2 gr every 12 hours and metronidazole 500 mg every 8 hours was started, with dexamethasone 4 mg every 12 hours and mannitol 18% in order to reduce the edema.

Cultures of blood and CSF resulted positive for *L. monocytogenes*. Transthoracic echocardiogram ruled out valvular vegetations and CT chest and abdomen showed no flogistic alterations. A final diagnosis of NL with brain abscess was established and i.v ampicillin 2 gr every 4 hours was started with progressive clinical improvement but he was subsequent transferred to an infectious disease unit in another hospital and lost at follow-up. Unfortunately, we have no information regarding the continuation of the therapeutic process and the prognosis.

Discussion

We presented a case of NL with an atypical presentation mimicking an ischemic stroke, with a delayed onset of fever and infections signs, in a male patient with a previous diagnosis of PMR.

To the best of our knowledge, up to 31 December 2025, this is the first case of a brain abscess with deep extension in the capsulo-thalamic region, compression of lateral ventricle and involvement of the corresponding leptomeningeal space, caused by *L. monocytogenes* in a PMR patient treated with MTX and PDN. The only other case report reported in literature regarding a NL is about a male patient with PMR taking PDN with a native vertebral osteomyelitis and an epidural abscess.²⁶ NL includes 4 major clinical entities: meningitis, meningoencephalitis, rhombencephalitis and brain abscess, and it may start with a stroke-like presentation. *L. monocytogenes* is the second agent responsible for acute bacterial meningitis after *Streptococcus Pneumoniae* in immunocompromised patients. According some epidemiological data, *L. monocytogenes* accounts for 16% of acquired bacterial meningitis in

adults >80 years, up to 22% of brain infections in immunocompromised adults, 2-7% in neonates and about 4% in young adults without risk factors.^{3,27-30} Brain invasion generally occurs in the context of a disseminated disease with bacteraemia, although the exact site of entry is not established. Probably *L. monocytogenes* can survive in the gastrointestinal tract, traversing the intestinal barrier (both penetrating through the M-cells in the Peyer's patches or by the direct invasion of intestinal epithelium mediated by specific internalins) and gaining access to the reticulo-endothelial system in the spleen and liver and finally passing in the bloodstream (if the host immune response is not able to contain the infection). *L. monocytogenes* can enter cells both *via* the normal phagocytic function of macrophages and other antigen presenting cells and different normally non-phagocytic cells such as enterocytes, fibroblasts, hepatocytes or endothelial cells. After internalization its PrfA-regulated virulence factors promote listerial intracellular survival. It uses intracellular metabolites and can spread directly from cytosol to cytosol avoiding the exposure to the extracellular host defence systems (e.g., antibodies, complement and neutrophils). Infection removal depends on cytosolic innate immunity and the mounting of an efficacious cell-mediated immune response involving tumor necrosis factor- α (TNF α), interferon γ , M1 (classically) activated macrophages, and major histocompatibility complex-class-II-restricted CD8+ T cells.³

L. monocytogenes can infect brain endothelial cells either directly or by cell-to-cell spreading from infected phagocytes entering into CNS through choroid plexus, ventricles, brain microvasculature [3] or *via* the trigeminal nerve by axonal spreading.^{3,21,31,32}

Risk factors for NL include older age, cancer, diabetes mellitus, use of GCs or other immunosuppressant drugs.³ Recently, a study identified inflammatory bowel diseases as another risk factor, probably linked to the use of anti-TNF α drugs; proton pump inhibitors usage could facilitate the enterocyte infection by inhibiting acid secretion in the stomach.^{33,34}

Patients with NL present with a slower onset of symptoms compared with other acute bacterial meningitis caused, for example, by meningococcus or pneumococcus. Although fever is frequently present (85-90% of cases), the classic bacterial meningitis triad of fever, neck stiffness and alteration of the mental status is less frequent, while 20% of patients develop a coma state and 10% present seizures.³

CT scan is the first imaging modality used in the diagnostic work-up of a stroke-like syndrome due to its availability and short time of acquisition. Although it could reveal macroscopic abscess, however, its sensitivity is low, in particular in the study of the posterior fossa or in meningoencephalitis and, as in our case, in the early phase could not discriminate between stroke and brain abscess.²⁸ Contrast-enhanced CT can show the size and location of the abscess with a surrounding rim enhancement. However, MRI, using diffusion weighted sequences and with the addition of the contrast medium has a sensitivity and a specificity of about 90% and it can distinguish between abscess and neoplasm.^{28,33} Using spectroscopy MRI, it can be possible to distinguish abscesses from rim-enhancing tumors and it can orientate towards the aetiology of the abscess according to the specific spectroscopic pattern found.³⁴

As far as listeriosis in people with rheumatic diseases (RMDs) was concerned, we found in literature 73 case reports (Table 1) and 4 case series (Table 2), for a total of 396 patients. Median age was about 54 years (age was not specified in every study), 54,8% were females, the majority regarding patients with rheumatoid arthritis (RA) receiving immunosuppressive therapy (namely GCs, MTX, anti-TNF α , among others) that presented predominantly with septic arthritis (mono, oligo or polyarticular both in native and prosthetic joints).³⁵⁻⁴⁶ One case was, curiously, associated with the use of acupuncture,⁴⁷ while another with intra-articular injection of Yttrium-90 therapy.³⁵ Other *L. monocytogenes* manifestations in RA patients included: sepsis, meningitis, rhombencephalitis, osteomyelitis, empyema, pericardial effusion and a splenic granuloma in a patient with Felty syndrome.⁴⁷⁻⁵⁶

Regarding other RMDs, there are cases in patients with juvenile idiopathic arthritis,⁵⁷ psoriatic arthritis, dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, GCA, sarcoidosis, and Still's disease.^{39,58-82} Tables 1 and 2 reassume the main characteristics of RMDs

patients with *L. Monocytogenes* infection. It can be noted that MTX and GCs are frequently used by patients who developed infection reflecting their central role and subsequent wide usage in the management of RMDs.

MTX is considered the anchor drug in the management of RA and as a steroid sparing agent in many other RMDs including PMR.^{16,82} MTX has multiple immunomodulating effects, repress T cell activation, downregulating B-cell function and increasing the sensitivity of activated CD-95 T cells. Additionally inhibits the binding of Interleukin-1 to its cell surface receptor. These effects may, eventually favor *L. monocytogenes* infection and dissemination.^{66,67} MTX is generally considered safe with regard to the infection risk, however, even low doses of MTX have been associated with *L. monocytogenes* infection.^{68,69}

Since many years, GCs are considered another well-known risk factor for invasive listeriosis both in humans and in animal models with high morbidity and mortality.⁷⁰ They lead to alteration of cellular and humoral immunity and impair intracellular killing by membrane stabilization facilitating the spreading of the infection. Moreover, it has to be said that many cases patients were also taking concomitant immunosuppressive drugs boosting those effects.⁷⁰⁻⁸²

So in our case, it is reasonable to suppose that the use of GC, even if at low/medium dosage, associated with MTX could have favored, in a cumulative manner, the infection and the subsequent brain invasion, it is interesting to note that the patient has a slight hypogammaglobulinemia probably induced by the immunosuppressive treatment. Unfortunately, we could not find a certain source of infection, in particular patient denied to consume raw milk products. Moreover his age was higher of the median age of previous cases and he also can be considered frail due to hi comorbidities.

The uniqueness of this case also lies in its atypical presentation, which featured an acute, stroke-like onset. The subsequent appearance of fever and other infectious signs only two days after admission complicated clinical management, as initial efforts focused solely on the suspected cerebrovascular event, thereby delaying the initiation of empirical antibiotic therapy. Another abnormality is the absence of pleocytosis in CSF. In their paper Gabriel Horta-Baas *et al.* found the presence of liquor pleocytosis in all the cases they analyzed with a predominancy of polymorphonuclear cells.⁶⁹

In this regard, it is plausible that the immunosuppression had blunt the immune response of the patient slowing the appearance of the systemic response to the infection thus mimicking an acute cerebrovascular accident and probably preventing the development of CSF pleocytosis. Moreover, brain abscess could have an hematogenous origin with subsequent (asymptomatic bacteremia?), contiguous involvement of leptomeninges, thus explaining the absence of CSF pleocytosis because there is first cerebritis rather than meningoencephalitis. It has to be said that CFS has been rapidly analyzed after the collection, so it is unlikely that accidental degradation of white blood cells has occurred.

This, also, stresses the importance of obtaining early, pre-antibiotic, blood cultures in immunocompromised patients with a low threshold in order to isolate opportunistic pathogens and promptly institute an appropriate antimicrobial treatment.

Limitations of this study include: a lack of follow-up due to the patient's transfer to another hospital in a different city, which precluded the assessment of the final clinical outcome, additionally, the definitive source of infection could not be identified. Regarding the latter, we do not have access to the results of the microbiological tests conducted by the public health office. However, establishing clear risk factors is frequently challenging in cases of listeriosis. *L. monocytogenes* can contaminate both processed and unprocessed food supply chains at multiple stages, and even low-level contamination can be clinically significant. Furthermore, potential vehicles of infection are numerous given the bacterium's remarkable environmental resilience. This epidemiological complexity is compounded by a variable incubation period, notably prolonged in cases involving pregnancy or CNS infections,² which further hinders retrospective source tracking.

Lastly, a stool culture was not performed, which could have provided valuable insights regarding gastrointestinal colonization by *L. monocytogenes*.

Conclusions

Although Stroke-like appearance is a rare, well known, manifestation on NL,^{3,26,27} this is the first case in a patient with a RMD, specifically PMR. We reported the case of a patient with PMR treated with GCs and MTX who, insidiously, developed a cerebral abscess with involvement of leptomeningeal space due to *L. monocytogenes* mimicking an acute ischemic stroke. Immunosuppression, even low doses, long term of GCs and MTX represented a risk factor for the infection. Moreover this case report underlies the atypical presentation that NL can have in immunocompromised patients mimicking cerebrovascular accident and delaying the correct diagnosis even confounding laboratory tests. An high index of suspicion is needed and microbiological samples must be obtained in order to promptly start an adequate antimicrobial therapy and improves survival.

References

1. Charliera A, Disson O, Lecuit M. Maternal-neonatal listeriosis. *Virulence* 2020;11:391-7.
2. Matle I, Mbatha KR, Madoroba E. A review of *Listeria monocytogenes* from meat and meat products: Epidemiology, virulence factors, antimicrobial resistance and diagnosis. *Onderstepoort J Vet Res* 2020;87:e1-20.
3. Koopmans MM, Brouwer MC, Vazquez-Boland JA, va de Beek D. Human listeriosis. *Clin Microbiol Rev* 2023;36:e0006019.
4. Holch A, Webb J, Lukjancenko O, et al. Genome sequencing identifies two nearly unchanged strains of persistent *Listeria monocytogenes* isolated at two different fish processing plants sampled 6 years apart. *Appl Environ Microbiol* 2013;79:2944-51.
5. Liu. D. Identification, subtyping and virulence determination of *Listeria monocytogenes*, an important foodborne pathogen. *J Med Microbiol* 2006;55:645-59.
6. European Center for Disease Prevention and Control. Listeriosis - Annual epidemiological report for 2016. Available from: <https://www.ecdc.europa.eu/en/publications-data/listeriosis-annual-epidemiological-report-2016>.
7. De las Heras A, Cain RJ, Bielecka MD, Vazquez-Boland JA. Regulation of *Listeria* virulence: PrfA master and commander. *Curr Opin Microbiol* 2011;14:118-27.
8. Lecuit M. Human listeriosis and animal models. *Microbes Infect* 2007;9:1216-25.
9. Freitag NE, Port GC, Miner MD. *Listeria monocytogenes*- from saprophyte to intracellular pathogen. *Nat Rev Microbiol* 2009;7:623-8.
10. Kreft J, Vazquez-Boland JA. Regulation of virulence genes in *Listeria*. *Int J Med Microbiol* 2001;291:145-57.
11. Scortti M, Monzó HJ, Lacharme-Lora L, et al. The PrfA virulence regulon. *Microbes Infect* 2007;9:1196-207.
12. Charlier C, Perrodeau E, Leclercq A, et al. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. *Lancet Infect Dis* 2017;17:510-9.
13. Lundberg IE, Sharma A, Turesson C, Mohammad AJ An update on polymyalgia rheumatica. *J Intern Med* 2022;292:717-32.
14. Falsetti P, Manzo C, Isetta M, et al. Review are there definite disease subsets in polymyalgia rheumatica? Suggestions from a narrative review. *Healthcare* 2025;13:1226.
15. Dejaco C, Singh YP, Perel P, et al. Recommendations for the management of polymyalgia rheumatica: a European League against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis* 2015;74:1799-807.
16. Baral B, Parajuli M, Pinilla J, et al. Efficacy and safety of Tocilizumab in polymyalgia rheumatica: a systematic review and meta-analysis of randomized controlled trials. *ARP Rheumatol* 2025;4:145-53.
17. García-Porrúa C, Heras-Recuero E, Blazquez-Sanchez T, et al. Review traditional and emerging strategies for managing polymyalgia rheumatica: insights into new treatments. *J Clin Med* 2024;13:6492.

18. Singh JA, Cleveland JD. Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study. *Clin Rheumatol* 2020;39:3427-38.
19. Tanakaa Y, Tanaka S, Fukasawa T, et al. Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: a cohort study using routinely collected health data. *Joint Bone Spine* 2024;91:105680.
20. Ruediger C, Nguyen L, Black R, et al. Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care. *Intern Med J* 2020;50:1067-72.
21. Ibrahim A, Ahmed M, Conway R, Carey J. Risk of infection with methotrexate therapy in inflammatory diseases: a systemic review and meta-analysis. *J Clin Med* 2018;8:15.
22. Sharma M, Das SK, Mohindra R, Dutta D. Safety of tocilizumab in polymyalgia rheumatica: a systematic review and meta-analysis. *Int J Rheum Dis* 2025;28:e70106.
23. Huang X, Ling Y, Tan S, et al. Cognitive reserve, frailty status, and risk of neurodegenerative diseases: a prospective cohort study. *NPJ Parkinsons Dis* 2025;12:20.
24. Zhang Y, Xia H, Jiang X, et al. Prevalence and outcomes of cognitive frailty: a systematic review and meta-analysis. *Res Gerontol Nurs* 2024;17:202-12.
25. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. *Psychother Psychosom* 2022;91:8-35.
26. Ibironke O, Sommer J, Idowu AB, et al. Vertebral osteomyelitis and epidural abscess due to *Listeria monocytogenes*—case report and review of literature. *J Bone Joint Infect* 2022;7:75-9.
27. Zawadzki R, Rogalska W, Paldyna M, et al. Imaging modalities in neurolisteriosis: a literature review. *Pol J Radiol* 2024;89:e345-57.
28. Shimizu H, Imoto H, Hara S, Nishioka N. Case report *Listeria rhombencephalitis* mimicking stroke in a patient with giant cell arteritis. *J Infect Chemother* 2023;29:703-6.
29. Karlsson WK, Harboe ZB, Roed C, et al. Early trigeminal nerve involvement in *Listeria monocytogenes rhombencephalitis*: case series and systematic review. *J Neurol* 2017;264:1875-84.
30. Zhang Z, Liu T, Qian R, et al. Global burden of *Listeria monocytogenes* meningitis in children, 1990–2021: an analysis from the Global Burden of Disease Study 2021. *Transl Pediatr* 2025;14:1854-65.
31. Dragomir RM, Mattner O, Hagan V, Swerdloff MA. *Listeria monocytogenes* brain abscess presenting with stroke-like symptoms: a case report. *Cureus* 2024;16:e52216.
32. Sheybani F, Brouwer MC, Lowenberg M, van de Beek. Community-acquired bacterial meningitis in patients with inflammatory bowel diseases. *J Infect* 2022;85:573-607.
33. Rogalla D, Bomar PA. *Listeria monocytogenes*. Treasure Island, FL, USA: StatPearls Publishing.
34. Wilson APR, Prouse PJ, Gumpel JM. Case report *Listeria monocytogenes* septic arthritis following intra-articular yttrium-90 therapy. *Ann Rheum Dis* 1984;43:518-9.
35. Booth LV, Walters MT, Tuck AC, et al. *Listena monocytogenes* infection in a prosthetic knee joint in rheumatoid arthritis. *Ann Rheum Dis* 1990;49:58-9.
36. Ukkonen HJ, Vuori KP, Lehtonen OP, Kotilainen PM. *Listeria monocytogenes* arthritis of several joints. *Scand J Rheumatol* 1995;24:392-4.
37. Schett G, Herak P, Graninger W, et al. *Listeria*-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. *J Clin Microbiol* 2005;43:2537-41.
38. Kesteman T, Yombi JC, Gigi J, Durez P. *Listeria* infections associated with infliximab: case reports. *Clin Rheumatol* 2007;26:2173-5.
39. Newman JH, Waycott S, Cooney LM. Arthritis due to *Listeria monocytogenes*. *Arthritis Rheum* 1979;22:1139-40.
40. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. *Arthritis Rheum* 2006;54:2368-76.

41. Salmon-Ceron D, Tubach F, Lortholary O, et al. For the RATIO group drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. *Ann Rheum Dis* 2011;70:616-23.
42. Bodro M, Paterson DL. Listeriosis in patients receiving biologic therapies. *Eur J Clin Microbiol Infect Dis* 2013;32:1225-30.
43. Silfman NR, Gershon SK, Lee JH, et al. *Listeria monocytogenes* infection as a complication of treatment with tumor necrosis factor-neutralizing agents. *Arthritis Rheum* 2003;48:319-24.
44. Peña-Sagredo JL, Hernandez MV, Fernandez-Llanio N, et al. *Listeria monocytogenes* infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. *Clin Exp Rheumatol* 2008;26:854-9.
45. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis* 2004;38:1261-5.
46. Chiung-Hsi Tien A, Huang GS, Chang CC, et al. Acupuncture-associated *Listeria monocytogenes* arthritis in a patient with rheumatoid arthritis. *Joint Bone Spine* 2008;75:502-3.
47. Pagliano P, Attanasio V, Fusco U, et al. Does etanercept monotherapy enhance the risk of *Listeria monocytogenes* meningitis? *Ann Rheum Dis* 2004;63:462-3.
48. Tweezer-Zaks N, Shiloach E, Spivak A, et al. *Listeria monocytogenes* sepsis in patients treated with anti-tumor necrosis factor-alpha. *IMAJ* 2003;5:829-30.
49. Murphy G, Schmidt-Martin D, Hynes BG, Harney S. Systemic listeriosis with adalimumab therapy. *J Clin Rheumatol* 2009;15:369-70.
50. Benji K, Chuang C, Rawal A, Gertner E, et al. *Listeria rhomboencephalitis* in a patient on a tumor necrosis factor α inhibitor (etanercept). *J Clin Rheumatol* 2014;20:325-7.
51. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. *Listeria meningitis* associated with infliximab. *Ann Pharmacother* 2004;38:58-61.
52. Kubota T, Mori Y, Yamada G, et al. *Listeria monocytogenes* ankle osteomyelitis in a patient with rheumatoid arthritis on adalimumab: a report and literature review of *Listeria monocytogenes* osteomyelitis. *Intern Med* 2021;60:3171-6.
53. Sim JS, Kim MJ, Jung JH, et al. Nosocomial empyema caused by a rare serotype, serotype 4c, of *Listeria monocytogenes* in a patient with rheumatoid arthritis and chronic kidney disease: a case report and review of the literature. *J Infect Chemother* 2015;21:824-7.
54. Crellin AM, Shareef DS, Maher EJ. Opportunistic *Listeria* pericardial effusion. *Postgrad Med J* 1990;66:203-4.
55. Inhorn SL, Smits RL, Christenson E. *Listeria* as a cause of splenic granulomas in a patient with Felty's syndrome. *Am J Clin Pathol* 1960;33:330-8.
56. Turner D, Fried M, Hoffman M, et al. Brainstem abscess and meningitis due to *Listeria monocytogenes* in an adult with juvenile chronic arthritis. *Neurology* 1995;45:1020-1.
57. Wang HL, Ghanem KG, Wang P, et al. Listeriosis at a tertiary care hospital in Beijing, China: high prevalence of non clustered healthcare-associated cases among adult patients. *Clin Infect Dis* 2013;56:666-76.
58. Marangos MN, Keroack BJ, Claffey TF. *Listeria monocytogenes* joint infection in a patient with psoriatic arthritis. *J Rheumatol* 1996;23:2005-6.
59. Zhang NA, Sun W, Zhou L, et al. Multiple brain abscesses due to *Listeria monocytogenes* infection in a patient with systemic lupus erythematosus: a case report and literature review. *Int J Rheum Dis* 2021;24:142-39.
60. Nadarajah K, Pritchard C. *Listeria monocytogenes* septic arthritis in a patient treated with etanercept for rheumatoid arthritis. *J Clin Rheumatol* 2005;11:120-2.
61. Rachapalli S, O'Daunt S. Septic arthritis due to *Listeria monocytogenes* in a patient receiving etanercept. *Arthritis Rheum* 2005;52:987-90.
62. Gluck T, Linde HJ, Schölmerich J, et al. Anti-tumor necrosis factor therapy and *Listeria monocytogenes* infection: report of two cases. *Arthritis Rheum* 2002;46:2252-64.
63. Paranjape N. Rhombencephalitis due to *Listeria monocytogenes*. *IDCases* 2021;24:e01081.

64. Jansen TL, van Heereveld HA, Laan RF, et al. Septic arthritis with *Listeria monocytogenes* during low-dose methotrexate. *J Intern Med* 1998;244:87-90.
65. Hanoodi M, Mittal M. Methotrexate. Treasure Island, FL, USA: StatPearls Publishing; 2024.
66. Wollenhaupt J, Busche T, Zeidler H. *Listeria monocytogenes* Infection in a prosthetic knee joint in rheumatoid arthritis during methotrexate therapy. *J Clin Rheumatol* 1997;171-5.
67. Muzumdar D, Jhawar S, Goel A. Brain abscess: an overview. *Int J Surg* 2011;9:136-44.
68. Johnson ML, Colley EW. *Listeria monocytogenes* encephalitis associated with corticosteroid therapy. *J Clin Pathol* 1969;22:465-9.
69. Horta-Baasa G, Guerrero-Soto O, Barile.Fabris L. Central nervous system infection by *Listeria monocytogenes* in patients with systemic lupus erythematosus: analysis of 26 cases, including the report of a new case. *Reumatol Clin* 2013;9:340-7.
70. Schulze ML, Wahle JB. Meningitis due to *Listeria monocytogenes* in a case of disseminated lupus erythematosus. *Am J Clin Pathol* 1953;23:1028-30.
71. Rosengarten R, Bourn JM. *Listeria* septicemia and meningitis in a case of lupus erythematosus. *Neurology* 1959;9:704-6.
72. Harisdangkul V, Songcharoen S, Lin AC. Listerial Infections in patients with systemic lupus erythematosus. *South Med J* 1992;85:957-60.
73. Kraus A, Cabral AR, Sifuentes-Osornio J, Alarcon-Segovia D. Listeriosis in patients with connective tissue diseases. *J Rheumatol* 1994;21:635-8.
74. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with *Listeria monocytogenes*: 33 years' experience at a general hospital and review of 776 episodes from the literature. *Medicine* 1998;77:313-36.
75. Eckburg PB, Montoya JG, Vosti KL. Abscess due to *Listeria monocytogenes*: five cases and a review of the literature. *Medicine* 2001;80:223-35.
76. Hung JJ, Ou LS, Lee WI, Huang JL. Central nervous system infections in patients with systemic lupus erythematosus. *J Rheumatol* 2005;32:40-3.
77. Cone LA, Somero MS, Qureshi FJ, et al. Unusual infections due to *Listeria monocytogenes* in the Southern California Desert. *Int J Infect Dis* 2008;12:578-81.
78. Baizabal-Carvallo JF, Delgadillo-Marquez G, Estañol B, et al. Clinical characteristics and outcomes of the meningitides in systemic lupus erythematosus. *Eur Neurol* 2009;61:143-8.
79. Tobo GJ, Serna MJ, Cañas CA. *Listeria monocytogenes* infection in patients with systemic lupus erythematosus. *Clin Rheumatol* 2013;32:25-7.
80. Lee MC, Wu YK, Chen CH, et al. *Listeria monocytogenes* meningitis in a young woman with systemic lupus erythematosus. *Rheumatol Int* 2011;31:555-7.
81. McCaffrey LM, Petelin A, Cunha BA. Systemic lupus erythematosus (SLE) cerebritis versus *Listeria monocytogenes* meningoencephalitis in a patient with systemic lupus erythematosus on chronic corticosteroid therapy: the diagnostic importance of cerebrospinal fluid (CSF) of lactic acid levels. *Heart Lung* 2012;41:394-7.
82. Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2026;82:3-18.

Table 1. Case reports of rheumatic disease patients with *Listeria monocytogenes* infection.

N.	Author[ref]	Sex, age	RMDs	Treatment	Type of listeriosis infection
1	Nadarajah <i>et al.</i> ⁶⁰	M, 63 Y	RA	MTX, PRD, ETA	Septic arthritis, NJ
2	Wilson <i>et al.</i> ³⁴	M, 70 Y	RA	IA yttrium-90 injection	Septic arthritis, NJ
3	Inhorn <i>et al.</i> ⁵⁶	F, 48 Y	RA/Felty's syndrome	GCs	Splenic granuloma
4	Booth <i>et al.</i> ³⁵	F, 64 y	RA	GCs, gold, AZA, PEN, PHEN	Septic arthritis, PJ
5	Rachapalli <i>et al.</i> ⁶¹	M, 65	RA	ETA, PRD	Septic arthritis, NJ
6	Pagliano <i>et al.</i> ⁴⁷	M, 45	RA	ETA	Meningitis
7	Tweezer-Zaks <i>et al.</i> ⁴⁸	F, 55	RA	IFX, PRD, MTX	Sepsis
8	Murphy ⁴⁹	F, 58	RA	MTX, ADA, CS	Sepsis
9	Gluck <i>et al.</i> ⁶²	F, 60	RA	IFX, MTX, PRD, CyA	Meningoencephalitis, sepsis
10	Gluck <i>et al.</i> ⁶²	F, 62	RA	MTX, CyA, IFX	Brain abscess
11	Tien <i>et al.</i> ⁴⁶	M, 78	RA	MTX, PRD, HCQ, COXIB,	Septic arthritis NJ, after acupuncture
12	Turner <i>et al.</i> ⁵⁶	M, 19	JIA	High dose PRD, Colc	Meningitis, brainstem abscess
13	Benji <i>et al.</i> ⁵⁰	F, 87	RA	ETA, HCQ	Rhombencephalitis
14	Kesteman ³⁸	F, 52	MCTD	MTX, IFX, CS	Sepsis, terminal ileitis
15	Kesteman ³⁸	M, 79	RA	MTX, IFX, CTS	Sepsis, NJ septic arthritis
16	Ukkonen <i>et al.</i> ³⁶	F, 73	RA	Gold, CCs, Antimalarials, SZ, PEN	Oligoarthritis NJ
17	Huan-Ling <i>et al.</i> ⁵⁷	F, 47	DM	PRD	Meningitis
18	Huan-Ling <i>et al.</i> ⁵⁷	F, 56	SLE	PRD, CYC	Sepsis, MOF
19	Huan-Ling <i>et al.</i> ⁵⁷	F, 23	SLE	PRD	Acute liver failure hepatic encephalopathy, coma, GI bleed, respiratory failure
20	Huan-Ling <i>et al.</i> ⁵⁷	F, 33	SLE with nephropathy	PRD high dose	Sepsis
21	Huan-Ling <i>et al.</i> ⁵⁷	F, 43	DM	PRD, CYC	Sepsis, meningitis
22	Huan-Ling <i>et al.</i> ⁵⁷	F, 22	SLE with nephropathy	PRD, HCQ, DAP, MMF	Meningitis
23	Huan-Ling <i>et al.</i> ⁵⁷	M, 53	Still's disease	MTX, GCs	Meningitis
24	Huan-Ling <i>et al.</i> ⁵⁷	F, 18	SLE	none	Meningitis
25	Huan-Ling <i>et al.</i> ⁵⁷	M, 74	DM	none	Meningitis
26	Huan-Ling <i>et al.</i> ⁵⁷	F, 53	SLE with nephropathy	PRD, CYC	Meningitis
27	Huan-Ling <i>et al.</i> ⁵⁷	F, 45	MCTD	PRD	Meningitis
28	Huan-Ling <i>et al.</i> ⁵⁷	F, 49	DM	none	Sepsis
29	Huan-Ling <i>et al.</i> ⁵⁷	M, 59	DM	none	Meningitis
30	Crellin <i>et al.</i> ⁵⁴	F, 58	RA	PRD	Pericardial effusion
31	Venita Bowie <i>et al.</i> ⁵¹	M, 73	RA	IFX, MTX, PRD	Meningitis
32	Georg Schett <i>et al.</i> ³⁷	F, 54	RA	ETA, MTX	Septic arthritis NJ
33	Peña-Sagredo <i>et al.</i> ⁴⁴	F, 63	PsA	IFX, MTX, PRD	Meningitis/sepsis
34	Peña-Sagredo <i>et al.</i> ⁴⁴	M, 57	PsA	IFX, MTX, PRD	Meningitis
35	Peña-Sagredo <i>et al.</i> ⁴⁴	F, 69	RA	ADA	Sepsis
36	Peña-Sagredo <i>et al.</i> ⁴⁴	F, 63	RA	IFX, MTX, PRD	Meningitis
37	Peña-Sagredo <i>et al.</i> ⁴⁴	F, 56	RA	IFX, MTX, PRD	Sepsis/Peritonitis
38	Peña-Sagredo <i>et al.</i> ⁴⁴	F, 36	RA	IFX, MTX, PRD	Endophthalmitis
39	Zhang <i>et al.</i> ⁵⁹	F, 53	SLE	CYC, PRD	Multiple brain abscesses
40	Kubota <i>et al.</i> ⁵²	M, 73	RA	ADA, MTP, Igaratimod	Osteomyelitis
41	Sung Sim <i>et al.</i> ⁵³	F, 67	RA	PRD	Pleuric empyema
42	Shimizu <i>et al.</i> ²⁸	F, 79	GCA	PRD, MTX	Rhombencephalitis mimicking stroke
43	Ibironke <i>et al.</i> ²⁶	M, 60	PMR	PRD	Vertebral osteomyelitis and epidural abscess
44	Wollenhau <i>et al.</i> ⁶⁶	M, 70	RA	MTX	Septic arthritis PJ
45	Paranjape <i>et al.</i> ⁶³	M, 46	DM	MTX	Rhombencephalitis
46	Jansen <i>et al.</i> ⁶⁴	F, 17	SLE	MTX, PRD	Septic arthritis NJ
47	Newman <i>et al.</i> ³⁹	F, 64	RA, psoriasis	MTX	Septic arthritis NJ
48	Dixon <i>et al.</i> ⁴⁰	M, 47	RA	IFX	Meningitis
49	Dixon <i>et al.</i> ⁴⁰	M, 67	RA	ETA	Septic arthritis
50	Dixon <i>et al.</i> ⁴⁰	F, 60	RA	ADA	Septic arthritis
51	Horta-Baas <i>et al.</i> [69]	F, 47	SLE	MMF 3 gr/die+ PRD 0,5 mg/Kg/D	Cerebral abscess
52	Schulze <i>et al.</i> ⁷⁰	F, 19	SLE	None	Meningitis, bacteriemia
53	Bourn <i>et al.</i> ⁷¹	F, 48	SLE	Steroids NS	Meningitis bacteriemia
54	Harisdangk <i>et al.</i> ⁷²	M, 31	SLE, chronic renal failure	PRD, nitrogen mustard	Meningitis bacteriemia
55	Kraus <i>et al.</i> ⁷³	F, 25	SLE	PRD (50 mg/d)	Meningitis
56	Kraus <i>et al.</i> ⁷³	F, 29	SLE, Fisher-Evans Syndrome	PRD 100 mg/d	Meningitis, bacteriemia
57	Kraus <i>et al.</i> ⁷³	F, 20	Inactive SLE, chronic renal failure	none	Meningitis
58	Kraus <i>et al.</i> ⁷³	F, 28	Inactive SLE	none	Meningitis
59	Kraus <i>et al.</i> ⁷³	F, 60	Inactive SLE	PRD 7,5 mg/d	Meningitis, bacteriemia
60	Kraus <i>et al.</i> ⁷³	M, 27	Active SLE	PRD 200 mg/d	Meningitis
61	Mylonakis <i>et al.</i> ⁷⁴	F, 16	SLE	Steroids, Azathioprine, MTX	Meningitis
62	Eckburg <i>et al.</i> ⁷⁵	F, 34	SLE, renal transplantation	Standard immunosuppression not specified	Brain abscess, bacteriemia
63	Eckburg <i>et al.</i> ⁷⁵	M, 50	Sarcoidosis	PRD 50	Brain abscess
64	Hung <i>et al.</i> ⁷⁶	F, 29	SLE	CY+PRDN	Meningitis
65	Hung <i>et al.</i> ⁷⁶	F, 24	SLE	PRDN	Meningitis
66	Hung <i>et al.</i> ⁷⁶	F, 22	SLE	HCQ+PRDN	Meningitis, bacteriemia
67	Cone <i>et al.</i> ⁷⁷	F, 56	SLE	PRD	Brain abscess, bacteriemia
68	Baizabal-Carvallo <i>et al.</i> ⁷⁸	F, 38	SLE	none	Multiple brain abscesses, meningitis
69	Tobon <i>et al.</i> ⁷⁹	F, 18	SLE	AZA+PRD	Meningitis, bacteriemia

70	Tobon <i>et al.</i> ⁷⁹	F,27	SLE, CRF in HD	MMF+PRD	Meningitis, bacteriemia
71	Tobon <i>et al.</i> ⁷⁹	F,18	SLE	MMF+PRD	Meningitis, bacteriemia
72	Lee <i>et al.</i> ⁸⁰	F,32	SLE	HCQ+MMF+MTP	Meningitis bacteriemia
73	Mc Caffrey <i>et al.</i> ⁸¹	M,57	SLE	PRD (20 mg/d)	Meningitis bacteriemia

ADA, adalimumab; AZA, azathioprine; CYA, cyclosporin-A; CYC, cyclophosphamide; Colc, colchicine; COXIB, COX-2 inhibitor; DAP, dapsone; DM, dermatomyositis; ETA, etanercept; GC, glucocorticoid; HCQ, hydroxychloroquine; IFX, Infliximab; JIA, juvenile idiopathic arthritis; MCTD, mixed connective tissue disease; MMF, mycophenolate mofetil; MTP, methylprednisolone; NJ, native joint; PEN, penicillamine; Phe, phenylbutazone; PJ, prosthetic joint; PRD, prednisolone; PRDN, prednisolone; PsA, psoriatic arthritis; SLE, systemic lupus erythematosus; SZ, sulfasalazine.

Table 2. Case series of rheumatic disease patients with *Listeria monocytogenes* infection.

N	Author	N.patients; sex; median age	Types of diseases	DMARD	Types of infection
1	Salmon-Ceron <i>et al.</i> ⁴¹	4; NS; NS	RA	Anti-TNF α NS	1 colitis+bacteriemia, 2 pneumonia+bacteraemia, 1 arthritis left shoulder
2	Bodro <i>et al.</i> ⁴²	266;60Y; F50,8%	RMD 127, IBD 101; CD 64; UC 25, hematologic disease 9; others 28	IFX 205; ETA 31; ADA 26; RTX 11; ABA 1; GOL 1	Listeriosis 116; meningitis or encephalitis 108; sepsis 42
3	Slifman <i>et al.</i> ⁴³	15; 69,5Y; F8, M 7	9RA; 9CD, 1 NR	14 IFX; 1 ETA ; 7 MTX;1 CYA; 2 AZA; 3 Mercaptopurine; 4 Mesalamine	1 septic arthritis, Sepsis/meningitis
4	Wallis <i>et al.</i> ⁴⁵	38; ns; ns.	NS	IFX 36; ETA 2	NS

ABA, abatacept; ADA, adalimumab; Anti-TNF α , anti tumor necrosis factor- α ; AZA, azathioprine; CD, Crohn disease; CYA, cyclosporin-A; DMARD, disease modifying anti-rheumatic drug; ETA, etanercept; GOL, golimumab; IBD, inflammatory bowel disease; IFX, infliximab; MTX, methotrexate; NS, not specified; RA, rheumatoid arthritis; RMD, rheumatic disease; RTX, rituximab; UC, ulcerative colitis.